Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Conditions
Interventions
Vancomycin inhalation powder
Placebo inhalation powder
+1 more
Locations
71
United States
Pulmonary Associates of Mobile
Mobile, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Miller Childrens Hospital MemorialCare Health System Pediatric Pulmonology
Long Beach, California, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
University of Southern California Keck Medical Center of USC
Los Angeles, California, United States
Start Date
September 20, 2017
Primary Completion Date
July 28, 2020
Completion Date
January 15, 2021
Last Updated
December 16, 2022
NCT04469439
NCT02417740
NCT06984679
NCT07484607
NCT05359991
NCT06616857
Lead Sponsor
Savara Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions